Haematological malignancies result from a heterogeneous mix of genetic mutations and 22 chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 23 antibody rituximab, or the BCR-ABL inhibitor imatinib, have proven to be effective 24 treatments in the management of some of these malignancies, though relapsing or refractory 25 disease is still common. Nucleic acid-based therapies have also entered the clinical arena, 26 providing an alternative, complementary approach. The forerunner of these therapies were 27 the antisense oligonucleotides, but their scope has expanded to include siRNA, microRNA, 28 decoy oligonucleotides and aptamers. These can be used either as mono-therapeutics, in 29 conjunction with current chemotherapy regimens, or in combination with each other to 1 improve therapeutic efficacy. Not only can these nucleic acid-based therapies silence target 2 genes, they also have the potential of restoring gene function. While challenges remain in 3 delivering effective doses of nucleic acid in vivo, these are steadily being met, suggesting an 4 optimistic future in the treatment of haematological malignancies. This review summarises 5 the application of nucleic acid-based therapeutics, particularly aptamers, in the diagnosis and 6 treatment of haematological malignancies. 7
Introduction 1
Cancer treatment strategies continue to evolve, with new drugs reaching the marketplace each 2 year and patient survival data increasing steadily. Treatments are now based not only on the 3 histopathological diagnosis of the lesion, but also on its underlying molecular basis. The use There have been numerous clinical trials using ASOs for a variety of disease processes, such 1 as infection, inflammation, cardiovascular disease and cancer. Not all have been effective, but 2 several are showing promise. One of these, Genasense (oblimersen) (Genta Inc), targets the 3 anti-apoptotic gene BCL-2, which is over-expressed in a wide variety of tumour types and is 4 associated with increased resistance to radiation and chemotherapy (Klasa et al 2002) . In cell 5 lines and animal models, this ASO has been shown to decrease tumour Bcl-2 expression and 6 promote apoptosis (Vogl & Gewirtz 2008 ). Phase II/III clinical trials have been conducted 7 with oblimersen (through intravenous and subcutaneous routes of administration) in patients 8 with chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), multiple 10 Rayburn ). Oblimersen has also been used in a number of combinations: with 11 dexamethasone for the treatment of relapsed or refractory multiple myeloma (phase III) 12 (NCT00017602); with fludarabine and cyclophosphamide (phase III: NCT00024440), or 13 fludarabine and rituximab in previously treated CLL patients (phase I/II: NCT00078234); or 14 with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in patients with 15 stages II to IV diffuse large B-cell lymphoma (phase I: NCT00736450) (phase II: 16 NCT00080847). When combined with fludarabine/cyclophasphamide in a phase III trial, 17 oblimersen has shown a significant 5-year survival benefit (O'Brien et al 2009). 18 
19
A number of clinical trials are being conducted with ASOs directed to other genes. These 20 include an ASO targeting C-MYB, a proto-oncogene encoding a nuclear binding protein that 21 plays a major role in cell cycle regulation in haematopoietic cells. This ASO has been 22 combined with chemotherapy and bone marrow transplantation in chronic myeloid leukaemia 23 (CML) patients (phase II: NCT00002592), and also in patients with advanced haematological 24 malignancies (phase I: NCT00780052) to purge the ex vivo bone marrow stem cells. It has 25 been shown to suppress C-MYB mRNA levels in approximately half of the patients studied 26 and to lead to complete cytogenetic remission post-transplantation (Vogl & Gewirtz 2008) . A 27 second gene associated with apoptosis inhibition is the X-linked inhibitor of apoptosis 28 (XIAP). The overexpression of XIAP inhibits apoptosis caused by chemotherapy, radiation 29 and growth-factor deprivation through inhibition of caspase activity and its overexpression in 30 AML is associated with a poor clinical outcome. In xenograft models, the ASO inhibited 31 XIAP protein expression and enhanced chemotherapeutic activity (Vogl & Gewirtz 2008) . In 32 addition, a phase I/II study testing the effectiveness of this ASO combined with 33 chemotherapy for refractory or relapsed AML patients has recently been completed 1 (NCT00363974), with a positive clinical response reported and limited side effects 2 (peripheral neuropathy in < 4% patients) (Aegera Therapeutics) (Schimmer et al 2009). 3 Enzon Pharmaceuticals Inc. have also tested the effectiveness of an ASO targeting the gene 4 encoding the hypoxia-inducible factor-1α (anti-HIF-1α, EZN-2968). HIF-1α has been 5 associated with cancer pathogenesis, with an increased level of the protein being associated 6 with an increased risk of metastasis and/or a poorer prognosis in most solid tumours (Evens growth factor receptor bound protein-2 (L-Grb-2) (Bio-Path Holdings Inc.) have commenced.
14 These aim to prevent specific protein translation and therefore inhibit the growth of 15 leukaemic cells (NCT01159028). A phase II trial is also planned which will combine an anti- 16 p53 ASO (Cenersen) (Eleos Inc.) to sensitise AML stem cells with conventional 17 chemotherapy (idarubicin and cytarabine) in order to improve the complete response rate in 18 AML patients 55 years of age or older who have previously shown no response 19 (NCT00967512). 20 
21
RNAi 22 Since its discovery in 1998, RNA interference (RNAi) has emerged as an alternative to anti- 23 sense oligonucleotides for switching off cancer-causing genes (Fire et al 1998) . The short 24 double-stranded RNAs are processed by Dicer and incorporated into an RNA-induced 25 silencing complex (RISC). The sense strand is cleaved during the formation of this complex 26 and the anti-sense strand guides the RISC to the complementary target mRNA, which is 27 cleaved by RISC ( Fig 2) (Bhindi et al 2007) . Several types of RNAi are commonly 28 employed, including short-interfering RNA (siRNA) ( Fig 1B) , short-hairpin RNA (shRNA) 29 and micro RNA (miRNA) ( Fig 1C) . All these are able to inhibit the conversion of mRNA 30 into protein (Rayburn & Zhang 2008) . One key advantage of RNAi is that each double- 31 stranded RNA can be used multiple times once inside the cells to degrade its target mRNA.
32
Therefore, siRNA has been shown to be more effective at low nanomolar doses (10 to 200 1 nM) in vitro, whereas ASOs require much higher doses (200 to 900 nM) to be effective When primary haematopoietic cells from CML patients were transfected with this siRNA, 9 BCR-ABL mRNA levels were down-regulated (Huang & Yang 2010) . In addition to 10 providing an effective growth inhibitory effect, induction of apoptosis was also observed. 11 Similarly, the targeting of MLL-AF4 (the result of a t(4;11) translocation associated with a 12 poor prognosis in infant ALL) resulted in reduced mortality in a SCID mouse xenograft 13 model, suggesting that targeted therapy of this translocation may lead to highly specific and 14 effective treatment of this form of leukaemia (Thomas et al 2005) . Finally, an siRNA against 15 the AML1/ETO fusion gene resulting from the t(8;21) translocation prevalent in AML M2 led 16 to a robust downregulation of the corresponding mRNA (Peer 2010). To date, however, no 17 human clinical trials have been published using siRNAs for the treatment of leukaemias or 18 lymphomas. 19 20 MicroRNAs (miRNA) are naturally occurring RNAs that are cleaved from 70-100 nucleotide 21 hairpin precursors to a mature 18-25 nucleotide sequence by a complex protein system that 22 includes Dicer, as well as RNase III Drosha ( Fig 1C) . Mature miRNA exert their regulatory However, miRNAs can also act as tumour suppressors, as they are generally down-regulated 7 during tumour development. It has, therefore, been suggested that restoring such tumour- overexpression has been associated with a higher complete remission rate, longer overall 14 survival and a trend for longer disease-free survival in cytogenetically-normal AML patients. 15 Therefore, delivering mir-181a directly to leukaemia cells, or using agents capable of 16 increasing endogenous levels of mir-181a, may provide a therapeutic benefit (Marcucci et al 17 
2011
). It has also been suggested that combining miRNAs that target oncogenes, with 18 miRNAs that restore tumour suppressor ability would provide a more favourable clinical Indeed, a STAT3 DO has been tested in phase I clinical trials in patients with relapsed or 10 refractory non-Hodgkin's lymphoma or multiple myeloma (NCT00511082) and advanced 11 leukaemia of MDS (NCT01029509). Interestingly, a complex DO has been designed in 12 which multiple cis elements have been engineered into a single oligonucleotide to target NF-13 κB, E2F, and STAT3 which could inhibit tumour growth in a murine model (Gao et al 2006) . 14 Recently, a STAT5 DO has been shown to suppress leukaemic cell growth and induce 15 apoptosis in a BCR-ABL-positive cell line, potentially leading to a novel therapeutic approach 16 in the treatment of imatinib-resistant CML (Wang et al 2011) . Once again, there is great 17 promise, but much more is required before these agents appear in the clinic. 18 19 Shape-Specific Recognition 20 Aptamers 21 Aptamers are also nucleic acids (DNA or RNA), but differ from the previously mentioned 22 nucleic acid species in that they bind to their target(s) in a manner similar to antibodies, with 23 their tertiary and quaternary structure -rather than primary sequence -being important ( Fig   24   1E ) (Rayburn & Zhang 2008 ). As such, they are also referred to as chemical antibodies. 25 Through internal base pairing, aptamers form complex shapes in association with their target 26 molecule with a high affinity (Fig 2) . While unmodified RNA aptamers are more susceptible 27 to hydrolysis, they do provide a much higher level of structural diversity than DNA aptamers binders are produced (see Fig 3) . These can then be modified, either for imaging, or improved The anti-nucleolin aptamer, AS1411, was the first nucleic acid based aptamer approved for An increasing number of pre-clinical studies using aptamers to target haematological 6 malignancies are being reported. For example, the CD33 aptamer has been shown to be 7 efficiently internalised by CD33 + myeloid cell lines and has the potential to deliver 21 There remains a number of challenges associated with nucleic acid-based approaches. These RNAi, necessitating the need for assisted delivery (Gewirtz 2007) . Therefore, aptamers, 26 which can be specifically optimised to be internalised into the cell via receptor-mediated 27 endocytosis, represent a valuable addition to the field of nucleic acid-based therapeutics.
Challenges Faced by Nucleic Acid Delivery

28
Indeed, during the selection process, target binding aptamers can be preferentially selected 29 which are internalised. One way of achieving this is to conduct cell SELEX at 37°C to Off-target effects have also been associated with the use of ASOs, RNAi and DOs, especially 4 for systemic delivery. However, more problematic is the off target silencing that occurs from 5 RNAi degradation products, an effect which is increasingly being recognised as a source of 6 unwanted medicinal side effects (Gewirtz 2007) . The same toxicity concerns that 7 compromise the use of siRNA apply to the use of miRNA as well. However, the fact that 8 miRNA regulates multiple gene functions adds yet another layer to the complexity of using 9 this for therapy. One miRNA, mir-155, effectively induces tumourigenesis, although its 10 systemic delivery leads to a detrimental modulation of innate immune responses. These 11 effects would necessitate packaging the miRNA into targeted nanoparticles, or viral vectors. 12 It has been shown that lipid-based delivery of miRNA is efficient but induces an 13 inflammatory response, while biodegradable polymers have a less pronounced effect on the 14 inflammatory response, but also shorter effects and reduced delivery efficiency (Li et al 15 
2009
). This method of encapsulating nucleic acids inside nanoparticles has been used to 16 deliver an ASO targeting the R2 subunit of ribonucleotide reductase, which has been shown 17 to contribute to chemoresistance in AML cells. The nanoparticles were functionalised 18 through the use of transferrin, shown to be overexpressed on cancer cells, including AML 25 Systemic delivery would be advantageous and provide more clinical appeal, in spite of the 26 above mentioned limitations. It is now becoming more common to link the siRNA to 27 compounds, such as ligands or peptides to achieve target specificity and nuclease resistance, 28 and thereby eliminate some of the non-targeted effects (Bhindi et al 2007) . However, 29 systemic delivery to leukocytes is thought to be even more challenging than to organs and 30 tissues due to their dispersal throughout the body (Peer 2010) . Aptamers represent a unique 31 alternative in their ability to specifically target cancer cells. Aptamers that target both 1 extracellular ligands, as well as intracellular proteins have been developed. Those that target 2 the extracellular domains of transmembrane receptor proteins can facilitate the entry of RNAi 3 into cells via receptor mediated endocytosis (Fig 2(ii) Pervaiz 2010). What makes aptamers such a perfect therapeutic is the difference between 5 them and other nucleic acid therapeutics. Aptamers, by themselves, are not necessarily 6 effective therapeutics. They can block their target function, and, if internalising aptamers are 7 selected, they can prove to be much more effective as therapeutics through the direct 8 conjugation of drugs or attaching nanoparticles as drug delivery devices. The choice of a 9 suitable therapeutic target is governed by the need to target cancerous cells while leaving 10 healthy cells intact. This is where both aptamers and RNAi come into their element. RNAi 11 can be used to target disease-specific sequences within the cell, while the aptamer can guide 12 the siRNA to the abnormal cell, thus minimising off-target effects. Aptamers have been 13 directly conjugated to siRNA and exhibited a reduction in gene expression similar to that 14 seen when the siRNA was administered to cells using oligofectamine (Chu et al 2006) . This 15 has benefits when considering the ability of RNAi to target the T315I point mutation in Abl 16 which promotes imatinib-resistance. Through the use of gene silencing, it is possible to 17 reverse this resistance (Hexner & Gewirtz 2005 ). If an aptamer were to be generated against 18 an internalised cell surface marker present on CML cells, such as CD33, it would be possible 19 to directly target these imatinib-resistant cells. This possibility highlights an additional 20 advantage with wide ranging potential. To target the aberrant gene, such as ABL, or its 21 mRNA, and thus prevent the abnormal protein, often resistant to protein-specific drugs, from 22 being expressed could effectively control the disease (Hexner & Gewirtz 2005 ). More than 23 50% of all T-ALL express activating NOTCH-1 mutations, as well as nodal and cutaneous 24 ALCL (Aifantis et al 2008, Zhao 2010) . Preclinical evidence using siRNA targeting Notch-1 25 in a mouse xenograft model showed a reduction in tumour growth and a prolonged survival.
It's Not Just a Nucleic Acid: Aptamer Conjugates
26
This indicates a potential role for the aptamer targeting T-ALL conjugated to the siRNA 27 silencing Notch-1. One approach yet to be attempted could be to combine the aptamer 28 KH1C12 generated by Sefah and colleagues, which targets the AML cell line HL60, with 29 either oblimersen, or an siRNA targeting bcl-2, and treating AML patients with all trans aptamer, an approach already used in the Tan lab to deliver targeted drug therapy using their 7 sgc8 aptamer (Fig 2 (iii) ) (Kang et al 2010) . One aptamer that binds to its target but does not What can we expect from the future? 24 The studies described highlight the great potential of nucleic acids as targeted therapeutics. 25 But what lies over the horizon? It has already been noted that combining nucleic acids with and one aptamer, already approved (Macugen) by the US FDA, it is a short step to putting 9 these together. siRNA or ASO could be packaged into liposomes or other nanocarriers that 10 specifically target cancerous cells through the use of internalising aptamers. Indeed, one of 11 the outstanding advantages with aptamers is the ability to rapidly select and optimise a 12 particular aptamer to a newly identified target, a process taking months rather than years.
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This would allow the integration of results of current clinical trials into new selection 14 strategies and thus produce more effective second or third generation therapeutics. It is also 15 becoming more widely recognised that while targeting one single oncogene may inhibit 16 growth of cells or even induce apoptosis, advanced cancers have numerous pathways by 17 which to evade treatment. Therefore, it is likely that it will be necessary to target multiple 18 oncogenes or pathways to eradicate the cancer and lead to long-lasting disease-free survival 19 (Rayburn & Zhang 2008 ). Indeed, one approach to silencing has been to use a cocktail of 20 siRNA targeting various sites within the gene of interest (Hexner & Gewirtz 2005 ). 21 Additionally, Gao et al. has suggested using complex DOs to replace the traditional drug 22 cocktail, which would have the benefit of removing the undesirable drug interactions often 23 seen with the complicated treatment regimens necessary to treat aggressive disease (Gao et al 24 2006). Again, the limitation to systemic delivery can be overcome through the use of 25 functionalised nanocarriers. Moreover, the strategy is not solely restricted to gene silencing -26 through the use of specific miRNAs, there is potential to up-regulate specific proteins, such 27 as those that would have an apoptotic effect on diseased cells. Nucleic acid therapeutics are set to make a major contribution to the treatment of malignant 31 disease. This is a field of increasing research priority and relevance. Indeed, the National 32 Institute of Health in the US has funded numerous projects in the field of aptamers: it 1 awarded nearly $6 million in grants funding RNAi and miRNA in 2009 and recently another 2 $1.6 million to research the role of miRNAs in cancer. Given the successes seen with 3 siRNA and ASOs against specific gene aberrations, and the ability of aptamers to specifically 4 target cancer cells, it is now timely to start combining these nucleic acid therapeutics to 5 achieve even more effective treatments. The problem of off-target effects can be reduced by 6 hiding non-specific nucleic acids inside nanoparticles that can be degraded once inside the 7 cell to release their contents, or directly conjugating these to aptamers to reduce the off-target 8 effects. Specific targeting will mean that nucleic acids targeting a critical pathway in 9 malignancy that is shared by normal cells, or that had significant off-target effects, can now 10 get a second chance as therapeutic treatments. Oligonucleotides can either be delivered as free molecules (i), conjugated directly to an 2 aptamer (ii), or within a functionalised nanocomplex (iii). Once inside the cell, decoy 3 oligonucleotides (DO) block transcription factors (TF) from starting the transcription of 4 genomic DNA (iv) to mRNA. Antisense oligonucleotides (ASO) bind to their target mRNA 5 and block translation of mRNA to protein (v). siRNA is first processed via DICER and is 6 incorporated into the RNA-induced silencing complex (RISC) (vi). During this process the 7 sense strand is separated from the anti-sense strand. The sense strand is degraded while the 8 anti-sense strand guides the RISC to its target mRNA, which is then cleaved. miRNA are 
